Abstracts Archive - Page 2108 of 2425 - ACR Meeting Abstracts

Abstract Number: 2164 • 2013 ACR/ARHP Annual Meeting
Rituximab In The Treatment Of Children With Systemic LUPUS Erythematosus: ONE Year Analysis Of 12 Patients
Ekaterina Alexeeva^1,2, Rina Denisova², Saniya Valieva², Tatyana Bzarova², Kseniya Isayeva², Tatyana Sleptsova², Elena Mitenko², Evgeniya Chistyakova^1,2, Anna Fetisova² and Elena Semikina³, ¹I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ²Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ³Clinical Laboratory, Scientific Center of Children's Health of RAMS, Moscw, Russia
Background/Purpose: Treatment of childhood systemic lupus erythematosus (SLE) is an ongoing problem because of the severity of the disease in some patients and the side-effects…
Abstract Number: 2165 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Patients With Poly-Articular Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Controlled Withdrawal Trials
Gil Amarilyo¹, Simon Tarp², Ivan Foeldvari³, Neta Cohen⁴, Tracy D. Pope⁵, Jennifer M.P. Woo⁶, Robin Christensen² and Daniel Furst⁵, ¹Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁴Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA, ⁶Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Although various biologic agents (BAs) are in use for polyarticular juvenile idiopathic arthritis (pJIA), a combined meta-analytic summary comparing the efficacy and safety among…
Abstract Number: 2166 • 2013 ACR/ARHP Annual Meeting
Infection Risk With Tumor Necrosis Factor Inhibitor Use In Polyarticular Juvenile Idiopathic Arthritis
Caroline Y Chang¹, Rika Meyer² and Katherine AB Marzan¹, ¹Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are extremely effective in treating Juvenile Idiopathic Arthritis (JIA). However, TNF-α is critical in immune function, raising concerns of…
Abstract Number: 2167 • 2013 ACR/ARHP Annual Meeting
23-Valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients: Anti-Tumor Necrosis Factor Therapy Role in Short and Long-Term Immunogenicity
Nadia E. Aikawa¹, Ivan L.A. França², Ana C. M. Ribeiro³, Adriana M. Sallum⁴, Eloisa Bonfa⁵ and Clovis A. Silva⁴, ¹Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²Division of Infectious Diseases, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ⁵Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: There is no study regarding short and long-term assessments of 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) under biologic therapy. The objectives…
Abstract Number: 2168 • 2013 ACR/ARHP Annual Meeting
Temporomandibular Joint Involvement and Quality Of Life In Juvenile Idiopathic Arthritis
Paula Frid^1,2, Ellen Nordal^3,4, Francesca Bovis⁵, Denise Marafon⁵, Donato De Angelis⁵, Sheila Oliveira⁵, Fabrizia Corona⁵, Gabrieli Simonini⁵, Joyce Davidson⁵, Helen Foster⁵, Rik Joos⁵, Ivan Foeldvari⁵, Michel Steenks⁵, Pekka Lahdenne⁵, Pavla Dolezalova⁵, Elena Palmisani⁵, Alberto Martini⁵, Angela Pistorio⁵ and Nicolino Ruperto⁵, ¹Department of Otorhinolaryngology, Division of Oral and Maxillofacial Surgery, University Hospital North Norway, Tromso, Norway, ²Public Dental Service Competence Centre of Northen Norway, Tromso, Norway, ³Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, ⁴Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁵Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy
Background/Purpose: Temporomandibular joint (TMJ) arthritis in childhood is seen in a substantial percentage of children with Juvenile idiopathic arthritis (JIA) and may lead to reduced mouth…
Abstract Number: 2169 • 2013 ACR/ARHP Annual Meeting
Short Term Efficacy Of Biologic Agents In Patients With Systemic Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Trials
Simon Tarp¹, Gil Amarilyo², Ivan Foeldvari³, Neta Cohen⁴, Tracy D. Pope⁵, Jennifer M.P. Woo⁶, Robin Christensen¹ and Daniel Furst⁵, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁴Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA, ⁶Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe subtype of JIA, which includes systemic features such as fever, rash, elevated inflammatory markers along with…
Abstract Number: 2149 • 2013 ACR/ARHP Annual Meeting
Safety Of Lower-Dose Diclofenac Submicron Particle Capsules Dosed Up To 12 Weeks In Patients With Osteoarthritis
Clarence Young¹ and Marc C. Hochberg², ¹Iroko Pharmaceuticals, Philadelphia, PA, ²Medicine, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis (OA) is the most common cause of disability in the US and is frequently managed with non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs, including diclofenac,…
Abstract Number: 2129 • 2013 ACR/ARHP Annual Meeting
The Diagnostic Utility Of Anterior Knee Pain and Pain With Activities In Identifying Knees With MRI-Detected Structural Damage In The Patellofemoral Joint: The Multicenter Osteoarthritis Study
Joshua J. Stefanik¹, Tuhina Neogi², Jingbo Niu², Neil A. Segal³, Cora E. Lewis⁴, Michael C. Nevitt⁵, Frank Roemer⁶, Ali Guermazi⁷ and David T. Felson⁸, ¹Clinical Epidemiology, Boston University, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁴Preventive Medicine, University of Alabama, Birmingham, Birmingham, AL, ⁵Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁶Klinikum Augsburg, Augsburg, Germany, ⁷Boston University, Boston, MA, ⁸Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: It is widely thought that patellofemoral joint (PFJ) pathology, a source of symptoms in knee osteoarthritis (OA), can be identified using patient history and…
Abstract Number: 2130 • 2013 ACR/ARHP Annual Meeting
Factors Associated With Two-Year Pain Experience Outcome In Knee Osteoarthritis
Jamie E. Rayahin¹, Joan S. Chmiel², Orit Almagor², Laura Belisle², Alison H. Chang³, Kirsten Moisio², Karen W. Hayes², Yunhui Zhang² and Leena Sharma², ¹University of Illinois, Chicago, Chicago, IL, ²Northwestern University, Chicago, IL, ³Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL
Background/Purpose: Few strategies to improve pain outcome in knee OA exist, in part because methods to evaluate this outcome are not established. ICOAP development…
Abstract Number: 2131 • 2013 ACR/ARHP Annual Meeting
Osteoarthritis Pain: Variability and Clinical Correlations
Thomas J. Schnitzer¹, Renita Yeasted², Leijan Huang³, Jennifer Duffecy⁴, Mark Begale⁴ and A. Vania Apkarian³, ¹PM&R and Int Med, Northwestern University, Chicago, IL, ²PM&R, Northwestern University, Chicago, IL, ³Physiology, Northwestern University, Chicago, IL, ⁴Preventive Medicine, Northwestern University, Chicago, IL
Background/Purpose: Although osteoarthritis (OA) is an intensely studied model of chronic pain, little is known about the temporal dynamics of OA pain intensity and how…
Abstract Number: 2132 • 2013 ACR/ARHP Annual Meeting
Short-Run Transitions In Pain States: Reflections Of Multiple Outcome Clinical Measures of Inadequate Pain Relief among Patients With Knee Osteoarthiritis
Stephanie Taylor¹, Christopher Black², Paul M. Peloso³, Philip G. Conaghan⁴, Leah Stokes², Mart A.F.J. van de Laar⁵, François Rannou⁶, Nigel K. Arden⁷ and Panagiotis Mavros², ¹Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, ²Global Health Outcomes, Merck, Whitehouse Station, NJ, ³Clinical Research, Merck Sharp & Dohme Corp., Rahway, NJ, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Rheumatology, University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, ⁶Physical Medicine and Rehabilitation Service, Paris-Descartes University, Cochin Hospital, Paris, France, ⁷NDORMS; MRC Lifecourse Epidemiology Unit, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom
Background/Purpose: Despite the importance of pain management in osteoarthritis (OA), there has been limited evidence confirming the adequacy of measuring pain relief in clinical practice setting. The objective of…
Abstract Number: 2133 • 2013 ACR/ARHP Annual Meeting
Neuropathic Pain After Primary Total Hip and Knee Arthroplasty
Anne Lubbeke¹, Gabor J. Puskas¹, Domizio Suva¹, Sylvette Bas², Cem Gabay², Axel Finckh³ and Pierre Hoffmeyer¹, ¹Orthopaedic Surgery, Geneva University Hospitals, Geneva, Switzerland, ²Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³Rheumatology, Geneva University Hospital, Geneva, Switzerland
Background/Purpose: A sizeable number of patients continue to suffer from pain after total joint arthroplasty (TJA). The reason for this is not well established in…
Abstract Number: 2134 • 2013 ACR/ARHP Annual Meeting
Responsiveness and Predictive Ability Of The Knee Society Scale (KSS) Score
Jasvinder A. Singh^1,2, Cathy Schleck³, W. Scott Harmsen⁴ and David Lewallen⁵, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³Mayo Clinic College of Medicine, Rochester, MN, ⁴Mayo Clinic, Rochester, MN, ⁵Orthopedics, Mayo Clinic college of medicine, Rochester, MN
Background/Purpose: The KSS questionnaire has previously been shown to have face, content and construct validity and test-retest reliability. Our objective was to assess the Responsiveness and Predictive…
Abstract Number: 2135 • 2013 ACR/ARHP Annual Meeting
Musculoskeletal Pain Explains Differences In Function At Time Of Surgery In Black TKR and THR Patients
Anthony Porter¹, Wenjun Li², Leslie R. Harrold¹, Milagros Rosal³, Philip Noble⁴, David Ayers², Patricia D. Franklin² and Jeroan Allison⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ³Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Baylor College of Medicine, Houston, TX, ⁵Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The existence of racial disparities in total knee (TKR) and total hip (THR) replacement outcomes is well established but not well understood. The burden…
Abstract Number: 2136 • 2013 ACR/ARHP Annual Meeting
Does Functional Gain and Pain Relief After TKR and THR Differ By Patient Obese Status?
Wenjun Li¹, Leslie R. Harrold², Jeroan Allison³, Courtland Lewis⁴, Thomas Bowen⁵, Patricia D. Franklin¹ and David Ayers¹, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ⁴Hartford Hospital, Hartford, CT, ⁵Geisinger, Danville, PA
Background/Purpose: Obesity is an important predictor of functional status and pain after total knee (TKR) and total hip (THR) replacement. However, variations in pre-post TKR…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].